← Back to home

HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)

Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) explained in plain language.

Never miss a new study

Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) trials appear

Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New treatment aims to spare patients from Voice-Box removal surgery

Disease control Not yet recruiting

This trial is testing a combination of chemotherapy and immunotherapy drugs (carboplatin/cisplatin, paclitaxel, and toripalimab) for adults with advanced throat cancer. The main goal is to see if this treatment can effectively control the cancer while allowing patients to keep th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)

Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)

Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) trials appear

New treatment aims to spare patients from Voice-Box removal surgery